bluebird bio (NASDAQ: BLUE) reported Q4 EPS of ($0.67), $0.10 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.2 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.